Annexon (NASDAQ:ANNX – Get Free Report) and Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Insider and Institutional Ownership
88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 12.7% of Annexon shares are held by company insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Annexon and Day One Biopharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Annexon | 0 | 0 | 6 | 0 | 3.00 |
| Day One Biopharmaceuticals | 0 | 1 | 7 | 1 | 3.00 |
Profitability
This table compares Annexon and Day One Biopharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Annexon | N/A | -38.99% | -33.90% |
| Day One Biopharmaceuticals | N/A | -22.40% | -19.79% |
Volatility & Risk
Annexon has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.46, suggesting that its stock price is 246% less volatile than the S&P 500.
Valuation and Earnings
This table compares Annexon and Day One Biopharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Annexon | N/A | N/A | -$134.24 million | ($1.05) | -3.86 |
| Day One Biopharmaceuticals | N/A | N/A | -$188.92 million | ($1.03) | -11.95 |
Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Summary
Day One Biopharmaceuticals beats Annexon on 6 of the 11 factors compared between the two stocks.
About Annexon
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.
